The French subcontractor Cenexi has signed an agreement with the American biotech Humanigen to produce Lenzilumab in France, a potential treatment under study against Covid-19, he announced on Wednesday.

Cenexi, a pharmaceutical subcontractor specializing in the formulation and development of innovative sterile products, will thus become the sole producer in France of this potential treatment for the next five years.

The batches will be produced in its factory in Hérouville-Saint-Clair, in Calvados.

Lenzilumab, a monoclonal antibody, aims to prevent and treat "cytokine shock" or "cytokine storm", an uncontrolled inflammatory reaction that appears to play a key role in severe cases of Covid-19.

It is in the process of being registered with the European and French health authorities.

Humanigen is also studying the effectiveness of this treatment in other inflammatory conditions, such as graft-versus-host disease in patients who have received a transplant of hematopoietic stem cells, cells made by the bone marrow.

Humanigen also entered into an agreement in September 2020 with the Swiss group Lonza, one of the main suppliers to the pharmaceutical sector in the world, for the production of this antibody.

Health

Covid-19: Easing of the health protocol at school expected in the coming days

Health

Covid-19: Olivier Véran promises “1,000 additional intensive care beds” without setting a deadline

  • Processing

  • Covid-19

  • Medication

  • Coronavirus

  • Health

  • 0 comment

  • 0 share

    • Share on Messenger

    • Share on Facebook

    • Share on Twitter

    • Share on Flipboard

    • Share on Pinterest

    • Share on Linkedin

    • Send by Mail

  • To safeguard

  • A fault ?

  • To print